Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future

Area of Science:

• Pharmacology
• Gastroenterology
• Cardiology

Background:

• The development of safer non-steroidal anti-inflammatory drugs (NSAIDs) faces a critical shift from addressing gastrointestinal (GI) toxicity to managing cardiovascular (CV) toxicity.
• Current NSAID development must balance efficacy with reduced GI and CV risks, presenting a significant challenge for pharmaceutical research.

Purpose of the Study:

• To review the current landscape of NSAID development, focusing on the evolving understanding of GI versus CV toxicity.
• To evaluate existing and emerging NSAID options, including coxibs, traditional NSAIDs (tNSAIDs) with proton pump inhibitors (PPIs), naproxcinod, and hydrogen sulfide (H2S)-releasing NSAIDs.
• To discuss the clinical considerations for selecting NSAIDs based on patient CV and GI risk profiles.

Main Methods:

• Literature review and synthesis of existing research on NSAID-related GI and CV toxicities.
• Analysis of the safety and efficacy profiles of various NSAID classes and specific agents.
• Discussion of therapeutic strategies, including comedication with PPIs, for mitigating NSAID-related risks.

Main Results:

• Coxibs demonstrate superior GI safety compared to tNSAIDs, making them suitable for low-CV-risk patients with a history of GI events.
• For patients with GI risks, tNSAIDs with PPIs or PN400 offer a cost-effective alternative to coxibs.
• Naproxcinod presents a potential alternative to coxibs and tNSAIDs but requires PPI co-administration in patients with GI risk factors due to significant GI bleeding risk.
• Early-stage H2S-releasing NSAIDs show promise, but the development of NSAIDs with both excellent GI and CV safety profiles remains an ongoing pursuit.

Conclusions:

• The choice of NSAID must be carefully individualized based on a patient's specific GI and CV risk factors.
• While coxibs offer GI benefits, their CV implications necessitate caution. Naproxcinod requires careful risk management for GI bleeding.
• Further research into novel NSAIDs, such as H2S-releasing agents, is crucial for developing safer therapeutic options with minimal GI and CV toxicity.